Development of peptide vaccines in dengue
Dengue is one of the most important arboviral infection worldwide, infecting up to 390 million people and causing 25,000 deaths annually. Although a licensed dengue vaccine is available, it is not efficacious against dengue serotypes that infect people living in South East Asia, where dengue is an e...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | en |
| Published: |
Bentham Science Publishers
2017
|
| Subjects: | |
| Online Access: | http://eprints.sunway.edu.my/538/1/Reginald%20K%20Development%20of%20peptide.pdf http://eprints.sunway.edu.my/538/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1831341357893943296 |
|---|---|
| author | Reginald, Kavita* Chan, Yanqi Plebanski, Magdalena Poh, Chit Laa * |
| author_facet | Reginald, Kavita* Chan, Yanqi Plebanski, Magdalena Poh, Chit Laa * |
| author_sort | Reginald, Kavita* |
| building | Sunway Campus Library |
| collection | Institutional Repository |
| content_provider | Sunway University |
| content_source | Sunway Institutional Repository |
| continent | Asia |
| country | Malaysia |
| description | Dengue is one of the most important arboviral infection worldwide, infecting up to 390 million people and causing 25,000 deaths annually. Although a licensed dengue vaccine is available, it is not efficacious against dengue serotypes that infect people living in South East Asia, where dengue is an endemic disease. Hence, there is an urgent need to develop an efficient dengue vaccine for this region. Data from different clinical trials indicate that a successful dengue vaccine must elicit both neutralizing antibodies and cell mediated immunity. This can be achieved by designing a multi-epitope peptide vaccine comprising B, CD8+ and CD4+ T cell epitopes. As recognition of T cell epitopes are restricted by human leukocyte antigens (HLA), T cell epitopes which are able to recognize several major HLAs will be preferentially included in the vaccine design. While peptide vaccines are safe, biocompatible and cost-effective, it is poorly immunogenic. Strategies to improve its immunogenicity by the use of long peptides, adjuvants and nanoparticle delivery mechanisms are discussed |
| format | Article |
| id | my.sunway.eprints.538 |
| institution | Sunway University |
| language | en |
| publishDate | 2017 |
| publisher | Bentham Science Publishers |
| record_format | eprints |
| spelling | my.sunway.eprints.5382019-07-03T08:57:13Z http://eprints.sunway.edu.my/538/ Development of peptide vaccines in dengue Reginald, Kavita* Chan, Yanqi Plebanski, Magdalena Poh, Chit Laa * QH301 Biology QR355 Virology Dengue is one of the most important arboviral infection worldwide, infecting up to 390 million people and causing 25,000 deaths annually. Although a licensed dengue vaccine is available, it is not efficacious against dengue serotypes that infect people living in South East Asia, where dengue is an endemic disease. Hence, there is an urgent need to develop an efficient dengue vaccine for this region. Data from different clinical trials indicate that a successful dengue vaccine must elicit both neutralizing antibodies and cell mediated immunity. This can be achieved by designing a multi-epitope peptide vaccine comprising B, CD8+ and CD4+ T cell epitopes. As recognition of T cell epitopes are restricted by human leukocyte antigens (HLA), T cell epitopes which are able to recognize several major HLAs will be preferentially included in the vaccine design. While peptide vaccines are safe, biocompatible and cost-effective, it is poorly immunogenic. Strategies to improve its immunogenicity by the use of long peptides, adjuvants and nanoparticle delivery mechanisms are discussed Bentham Science Publishers 2017-09-13 Article PeerReviewed text en http://eprints.sunway.edu.my/538/1/Reginald%20K%20Development%20of%20peptide.pdf Reginald, Kavita* and Chan, Yanqi and Plebanski, Magdalena and Poh, Chit Laa * (2017) Development of peptide vaccines in dengue. Current Pharmaceutical Design. ISSN 1381-6128 10.2174/1381612823666170913163904 |
| spellingShingle | QH301 Biology QR355 Virology Reginald, Kavita* Chan, Yanqi Plebanski, Magdalena Poh, Chit Laa * Development of peptide vaccines in dengue |
| title | Development of peptide vaccines in dengue |
| title_full | Development of peptide vaccines in dengue |
| title_fullStr | Development of peptide vaccines in dengue |
| title_full_unstemmed | Development of peptide vaccines in dengue |
| title_short | Development of peptide vaccines in dengue |
| title_sort | development of peptide vaccines in dengue |
| topic | QH301 Biology QR355 Virology |
| url | http://eprints.sunway.edu.my/538/1/Reginald%20K%20Development%20of%20peptide.pdf http://eprints.sunway.edu.my/538/ |
| url_provider | http://eprints.sunway.edu.my/ |